Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma

Vittoria Rufini, Maria Lucia Calcagni, Salvatore Maria Corsello, Giorgio Treglia, Paola Castaldi, Germano Perotti, Aldo Giordano, G Galli, Silvia Fanti

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Detection of recurrent disease is essential for treatment planning in patients with paraganglioma. The aim of this study was to compare 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy [whole-body and single-photon emission computed tomography (SPECT) computed tomography (CT) scanning] and fluorine-18-L-dihydroxyphenylalanine positron emission tomography CT (18F-DOPA PET-CT) in the re-staging of patients with known or suspected recurrent paraganglioma.
Original languageEnglish
Pages (from-to)575-582
Number of pages8
JournalNuclear Medicine Communications
Volume32
DOIs
Publication statusPublished - 2011

Keywords

  • 3-Iodobenzylguanidine
  • Adrenal Gland Neoplasms
  • Adult
  • Aged
  • Dihydroxyphenylalanine
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Paraganglioma
  • Paraganglioma, Extra-Adrenal
  • Pheochromocytoma
  • Positron-Emission Tomography
  • Recurrence
  • Retrospective Studies
  • Tomography, Emission-Computed, Single-Photon
  • Tomography, X-Ray Computed
  • Young Adult

Fingerprint

Dive into the research topics of 'Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma'. Together they form a unique fingerprint.

Cite this